{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:54:48Z","timestamp":1788184488597,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03541-3","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:52:54Z","timestamp":1774425174000},"page":"1967-1982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factor\u00a0XI Inhibitors in Atrial Fibrillation: Insights and Implications from Recent Trials"],"prefix":"10.1007","volume":"43","author":[{"given":"Rosemary B.","family":"Falama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie E.","family":"Piatski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Seifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen J. T.","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Shatzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"1","key":"3541_CR1","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1093\/cvr\/cvac196","volume":"119","author":"S Ninni","year":"2023","unstructured":"Ninni S, Nattel S. Factor\u00a0XIa inhibition in atrial fibrillation: insights and knowledge gaps emerging from the PACIFIC-AF trial. Cardiovasc Res. 2023;119(1):E111\u20134. https:\/\/doi.org\/10.1093\/cvr\/cvac196.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"3541_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14740\/cr972","volume":"11","author":"M Negreva","year":"2020","unstructured":"Negreva M, Zarkova A, Prodanova K, Petrov P. Paroxysmal atrial fibrillation: insight into the intimate mechanisms of coagulation. Cardiol Res. 2020;11(1):22\u201332. https:\/\/doi.org\/10.14740\/cr972.","journal-title":"Cardiol Res"},{"key":"3541_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ahj.2021.12.017","volume":"247","author":"B Gencer","year":"2022","unstructured":"Gencer B, Eisen A, Berger D, et al. Edoxaban versus warfarin in high-risk patients with atrial fibrillation: a comprehensive analysis of high-risk subgroups. Am Heart J. 2022;247:24\u201332. https:\/\/doi.org\/10.1016\/j.ahj.2021.12.017.","journal-title":"Am Heart J"},{"issue":"24","key":"3541_CR4","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.120.049768","volume":"142","author":"AH Katsanos","year":"2020","unstructured":"Katsanos AH, Kamel H, Healey JS, Hart RG. Stroke prevention in atrial fibrillation looking forward. Circulation. 2020;142(24):2371\u201388. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049768.","journal-title":"Circulation"},{"issue":"10","key":"3541_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"issue":"11","key":"3541_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"12","key":"3541_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"25","key":"3541_CR8","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1093\/eurheartj\/ehac250","volume":"43","author":"G Liuzzo","year":"2022","unstructured":"Liuzzo G, Patrono C. A novel inhibitor of factor\u00a0XIa as potential haemostasis-sparing anticoagulant for patients with atrial fibrillation. Eur Heart J. 2022;43(25):2354\u20135. https:\/\/doi.org\/10.1093\/eurheartj\/ehac250.","journal-title":"Eur Heart J"},{"issue":"2","key":"3541_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jdmv.2023.04.002","volume":"48","author":"NK Bentounes","year":"2023","unstructured":"Bentounes NK, Melicine S, Martin AC, Smadja DM, Gendron N. Development of new anticoagulant in 2023: prime time for anti-factor\u00a0XI and XIa inhibitors. J Med Vasc. 2023;48(2):69\u201380. https:\/\/doi.org\/10.1016\/j.jdmv.2023.04.002.","journal-title":"J Med Vasc"},{"key":"3541_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-024-01138-5","author":"JR Spruit","year":"2024","unstructured":"Spruit JR, de Vries TAC, Hemels MEW, Pisters R, de Groot JR, Jansen RWMM. Direct oral anticoagulants in older and frail patients with atrial fibrillation: a decade of experience. Drugs Aging. 2024. https:\/\/doi.org\/10.1007\/s40266-024-01138-5.","journal-title":"Drugs Aging"},{"key":"3541_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02049-w","author":"M Galli","year":"2024","unstructured":"Galli M, Occhipinti G, Ortega-Paz L, et al. Therapeutic potential of FXI inhibitors: hype or hope? Drugs. 2024. https:\/\/doi.org\/10.1007\/s40265-024-02049-w.","journal-title":"Drugs"},{"issue":"24","key":"3541_CR12","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","volume":"68","author":"BA Steinberg","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin\u00a0K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597\u2013604. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.966.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"3541_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1046\/j.1365-2516.2000.00053.x","volume":"6","author":"PH Bolton-Maggs","year":"2000","unstructured":"Bolton-Maggs PH. Factor\u00a0XI deficiency and its management. Haemophilia. 2000;6(Suppl 1):100\u20139. https:\/\/doi.org\/10.1046\/j.1365-2516.2000.00053.x.","journal-title":"Haemophilia"},{"issue":"6","key":"3541_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacc.2023.12.004","volume":"83","author":"JW Eikelboom","year":"2024","unstructured":"Eikelboom JW, Mundl H, Alexander JH, et al. Bleeding outcomes in patients treated with asundexian in phase\u00a0II trials. J Am Coll Cardiol. 2024;83(6):669\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.004.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"3541_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","volume":"147","author":"A Greco","year":"2023","unstructured":"Greco A, Laudani C, Spagnolo M, et al. Pharmacology and clinical development of factor\u00a0XI inhibitors. Circulation. 2023;147(11):897\u2013913. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062353.","journal-title":"Circulation"},{"issue":"1","key":"3541_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1055\/a-1984-7021","volume":"43","author":"I Koulas","year":"2023","unstructured":"Koulas I, Spyropoulos AC. A review of FXIa inhibition as a novel target for anticoagulation. Hamostaseologie. 2023;43(1):28\u201336. https:\/\/doi.org\/10.1055\/a-1984-7021.","journal-title":"Hamostaseologie"},{"key":"3541_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216314","author":"E Campello","year":"2022","unstructured":"Campello E, Simioni P, Prandoni P, Ferri N. Clinical pharmacology of factor\u00a0XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11216314.","journal-title":"J Clin Med"},{"issue":"8","key":"3541_CR18","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1055\/s-0042-1742366","volume":"122","author":"MT Zabczyk","year":"2022","unstructured":"Zabczyk MT, Hanarz M, Malinowski KP, et al. Active FXI can independently predict ischemic stroke in anticoagulated atrial fibrillation patients: a cohort study. Thromb Haemost. 2022;122(8):1397\u2013406. https:\/\/doi.org\/10.1055\/s-0042-1742366.","journal-title":"Thromb Haemost"},{"issue":"5","key":"3541_CR19","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.5114\/aoms.2015.54791","volume":"12","author":"P Kusak","year":"2016","unstructured":"Kusak P, Czarnecka D, Gissel M, Plens K, Butenas S, Undas A. Activated factor IX, factor\u00a0XI and tissue factor identify patients with permanent atrial fbrillation treated with warfarin who are at risk of ischemic stroke. Arch Med Sci. 2016;12(5):1000\u20137. https:\/\/doi.org\/10.5114\/aoms.2015.54791.","journal-title":"Arch Med Sci"},{"issue":"11","key":"3541_CR20","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/14779072.2016.1224179","volume":"14","author":"AJW Gulpen","year":"2016","unstructured":"Gulpen AJW, Ten Cate-Hoek AJ, Ten Cate H. Upstream versus downstream thrombin inhibition. Expert Rev Cardiovasc Ther. 2016;14(11):1273\u201382. https:\/\/doi.org\/10.1080\/14779072.2016.1224179.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"15","key":"3541_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1182\/blood.2023020719","volume":"143","author":"SA Moellmer","year":"2024","unstructured":"Moellmer SA, Puy C, McCarty OJT. Biology of factor\u00a0XI. Blood. 2024;143(15):1445\u201354. https:\/\/doi.org\/10.1182\/blood.2023020719.","journal-title":"Blood"},{"issue":"B","key":"3541_CR22","doi-asserted-by":"publisher","first-page":"B65","DOI":"10.1093\/eurheartjsupp\/suad070","volume":"25","author":"F Muscente","year":"2023","unstructured":"Muscente F, De Caterina R. The new in anticoagulation: factor\u00a0XI inhibitors. Eur Heart J Suppl. 2023;25(B):B65\u20138. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad070.","journal-title":"Eur Heart J Suppl"},{"issue":"8","key":"3541_CR23","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1161\/ATVBAHA.118.311193","volume":"38","author":"J Zilberman-Rudenko","year":"2018","unstructured":"Zilberman-Rudenko J, Reitsma SE, Puy C, et al. Factor\u00a0XII activation promotes platelet consumption in the presence of bacterial-type long-chain polyphosphate in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2018;38(8):1748\u201360. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311193.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"3541_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","volume":"78","author":"C Hsu","year":"2021","unstructured":"Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI. Factor\u00a0XI inhibition to uncouple thrombosis from hemostasis. J Am Coll Cardiol. 2021;78(6):625\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2021.06.010.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3541_CR25","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s10439-016-1771-7","volume":"45","author":"JL Sylman","year":"2017","unstructured":"Sylman JL, Daalkhaijav U, Zhang Y, et al. Differential roles for the coagulation factors XI and XII in regulating the physical biology of fibrin. Ann Biomed Eng. 2017;45(5):1328\u201340. https:\/\/doi.org\/10.1007\/s10439-016-1771-7.","journal-title":"Ann Biomed Eng"},{"issue":"3","key":"3541_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jtha.2022.10.005","volume":"21","author":"SE Reitsma","year":"2023","unstructured":"Reitsma SE, Holle LA, Bouck EG, et al. Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor\u00a0XI deficiency. J Thromb Haemost. 2023;21(3):467\u201379. https:\/\/doi.org\/10.1016\/j.jtha.2022.10.005.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"3541_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.hoc.2021.07.012","volume":"35","author":"MD Lewandowska","year":"2021","unstructured":"Lewandowska MD, Connors JM. Factor\u00a0XI deficiency. Hematol Oncol Clin North Am. 2021;35(6):1157\u201369. https:\/\/doi.org\/10.1016\/j.hoc.2021.07.012.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"3541_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1056\/NEJMe2414209","volume":"392","author":"DJ Angiolillo","year":"2025","unstructured":"Angiolillo DJ, Capodanno D. Uncoupling thrombosis and hemostasis by inhibiting factor\u00a0XI. N Engl J Med. 2025;392(4):400\u20133. https:\/\/doi.org\/10.1056\/NEJMe2414209.","journal-title":"N Engl J Med"},{"issue":"4","key":"3541_CR29","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jtha.2024.12.003","volume":"23","author":"GD Barnes","year":"2025","unstructured":"Barnes GD. New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis. J Thromb Haemost. 2025;23(4):1146\u201359. https:\/\/doi.org\/10.1016\/j.jtha.2024.12.003.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"3541_CR30","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1021\/acsptsci.3c00052","volume":"6","author":"S Wichaiyo","year":"2023","unstructured":"Wichaiyo S, Parichatikanond W, Visansirikul S, Saengklub N, Rattanavipanon W. Determination of the potential clinical benefits of small molecule factor\u00a0XIa inhibitors in arterial thrombosis. ACS Pharmacol Transl Sci. 2023;6(7):970\u201381. https:\/\/doi.org\/10.1021\/acsptsci.3c00052.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3541_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123157","author":"CH Nolte","year":"2024","unstructured":"Nolte CH. Factor\u00a0XI inhibitors \u2013 rising stars in anti-thrombotic therapy? J Neurol Sci. 2024. https:\/\/doi.org\/10.1016\/j.jns.2024.123157.","journal-title":"J Neurol Sci"},{"key":"3541_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2024.100179","author":"HA Badreldin","year":"2024","unstructured":"Badreldin HA, Alsuhebany N, Alzahrani M, et al. Abelacimab: a leap forward in anticoagulation with FXI and FXIa inhibition. Curr Res Pharmacol Drug Discov. 2024. https:\/\/doi.org\/10.1016\/j.crphar.2024.100179.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"10333","key":"3541_CR33","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor\u00a0XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase\u00a02 study. Lancet. 2022;399(10333):1383\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1.","journal-title":"Lancet"},{"key":"3541_CR34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407105","author":"JP Piccini","year":"2025","unstructured":"Piccini JP, Patel MR, Steffel J, et al. Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2407105.","journal-title":"N Engl J Med"},{"issue":"1","key":"3541_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","volume":"23","author":"M Sharma","year":"2024","unstructured":"Sharma M, Molina CA, Toyoda K, et al. Safety and efficacy of factor\u00a0XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase\u00a02, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2024;23(1):46\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(23)00403-9.","journal-title":"Lancet Neurol"},{"issue":"23","key":"3541_CR36","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2113194.","journal-title":"N Engl J Med"},{"key":"3541_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","volume":"277","author":"SS Jain","year":"2024","unstructured":"Jain SS, Mahaffey KW, Pieper KS, et al. Milvexian vs apixaban for stroke prevention in atrial fibrillation: the LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024;277:145\u201358. https:\/\/doi.org\/10.1016\/j.ahj.2024.08.011.","journal-title":"Am Heart J"},{"issue":"2","key":"3541_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jth.15577","volume":"20","author":"BA Yi","year":"2022","unstructured":"Yi BA, Freedholm D, Widener N, et al. Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor\u00a0XI and factor\u00a0XIa. J Thromb Haemost. 2022;20(2):307\u201315. https:\/\/doi.org\/10.1111\/jth.15577.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"3541_CR39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385(7):609\u201317. https:\/\/doi.org\/10.1056\/NEJMoa2105872.","journal-title":"N Engl J Med"},{"issue":"4","key":"3541_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1056\/NEJMoa2406674","volume":"392","author":"CT Ruff","year":"2025","unstructured":"Ruff CT, Patel SM, Giugliano RP, et al. Abelacimab versus rivaroxaban in patients with atrial fibrillation. N Engl J Med. 2025;392(4):361\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2406674.","journal-title":"N Engl J Med"},{"issue":"22","key":"3541_CR41","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","volume":"116","author":"H Zhang","year":"2010","unstructured":"Zhang H, L\u00f6wenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor\u00a0XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116(22):4684\u201392. https:\/\/doi.org\/10.1182\/blood-2010-04-277798.","journal-title":"Blood"},{"issue":"3","key":"3541_CR42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, Bethune C, Bhanot S, et al. Factor\u00a0XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1405760.","journal-title":"N Engl J Med"},{"issue":"2","key":"3541_CR43","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","volume":"7","author":"M Walsh","year":"2022","unstructured":"Walsh M, Bethune C, Smyth A, et al. Phase\u00a02 study of the factor\u00a0XI antisense inhibitor IONIS-FXIRx in patients with ESRD. Kidney Int Rep. 2022;7(2):200\u20139. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.011.","journal-title":"Kidney Int Rep"},{"key":"3541_CR44","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1055\/a-2043-0346","volume":"123","author":"M Galli","year":"2023","unstructured":"Galli M, Laborante R, Ortega-Paz L, et al. Factor\u00a0XI inhibitors in early clinical trials: a meta-analysis. Thromb Haemost. 2023;123:576\u201384. https:\/\/doi.org\/10.1055\/a-2043-0346.","journal-title":"Thromb Haemost"},{"issue":"9","key":"3541_CR45","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1111\/j.1538-7836.2006.02093.x","volume":"4","author":"X Wang","year":"2006","unstructured":"Wang X, Smith PL, Hsu MY, et al. Effects of factor\u00a0XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost. 2006;4(9):1982\u20138. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.02093.x.","journal-title":"J Thromb Haemost"},{"issue":"Supplement_1","key":"3541_CR46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130823","volume":"134","author":"GE Mair","year":"2019","unstructured":"Mair GE, Olson SR, Shatzel JJ. The safety of novel drugs targeting factor\u00a0XI and XII in human clinical trials: a systematic review. Blood. 2019;134(Supplement_1):4966. https:\/\/doi.org\/10.1182\/blood-2019-130823.","journal-title":"Blood"},{"issue":"6","key":"3541_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ph16060866","volume":"16","author":"Y Xia","year":"2023","unstructured":"Xia Y, Hu Y, Tang L. Factor\u00a0XIa inhibitors as a novel anticoagulation target: recent clinical research advances. Pharmaceuticals. 2023;16(6):6. https:\/\/doi.org\/10.3390\/ph16060866.","journal-title":"Pharmaceuticals"},{"key":"3541_CR48","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2023.50","volume":"19","author":"M Komiyama","year":"2024","unstructured":"Komiyama M, Iguchi M, Wada H, Ikeda T, Dan GA, Hasegawa K. What is the future position of factor\u00a0XIa inhibitors for patients with atrial fibrillation? Eur Cardiol Rev. 2024;19:e10. https:\/\/doi.org\/10.15420\/ecr.2023.50.","journal-title":"Eur Cardiol Rev"},{"issue":"7","key":"3541_CR49","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/ehjcvp\/pvae065","volume":"10","author":"F Gragnano","year":"2024","unstructured":"Gragnano F, Capolongo A, Galli M, Calabr\u00f2 P. OCEANIC-AF trial: factor\u00a0XI inhibitors revolution in atrial fibrillation is on hold. Eur Heart J Cardiovasc Pharmacother. 2024;10(7):575\u20137. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae065.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9","key":"3541_CR50","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M, Hirsch J, Kotler A, et al. Factor\u00a0XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129(9):1210\u20135. https:\/\/doi.org\/10.1182\/blood-2016-09-742262.","journal-title":"Blood"},{"issue":"7","key":"3541_CR51","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","volume":"36","author":"D Gailani","year":"2016","unstructured":"Gailani D, Gruber A. Factor\u00a0XI as a therapeutic target. Arterioscler Thromb Vasc Biol. 2016;36(7):1316\u201322. https:\/\/doi.org\/10.1161\/ATVBAHA.116.306925.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3541_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxae182","author":"J Edwards","year":"2024","unstructured":"Edwards J, Corey J, Coons JC. Exploring the therapeutic utility of the factor\u00a0XIa inhibitor asundexian. Am J Health Syst Pharm. 2024. https:\/\/doi.org\/10.1093\/ajhp\/zxae182.","journal-title":"Am J Health Syst Pharm"},{"key":"3541_CR53","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16799","author":"S Carlin","year":"2024","unstructured":"Carlin S, Jakovac M, Budaj A, Eikelboom J. Factor\u00a0XI inhibition in cardiovascular disease. Pol Arch Intern Med. 2024. https:\/\/doi.org\/10.20452\/pamw.16799.","journal-title":"Pol Arch Intern Med"},{"key":"3541_CR54","doi-asserted-by":"publisher","unstructured":"Rocca B, ten Cate H. Factor\u00a0XI and atrial fibrillation: a mismatched pairing? Eur Cardiol. https:\/\/doi.org\/10.15420\/ecr.2024.61.","DOI":"10.15420\/ecr.2024.61"},{"issue":"8","key":"3541_CR55","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1055\/s-0042-1742366","volume":"122","author":"MT Z\u0105bczyk","year":"2022","unstructured":"Z\u0105bczyk MT, Hanarz M, Malinowski KP, et al. Active FXI can independently predict ischemic stroke in anticoagulated atrial fibrillation patients: a cohort study. Thromb Haemost. 2022;122(8):1397\u2013406. https:\/\/doi.org\/10.1055\/s-0042-1742366.","journal-title":"Thromb Haemost"},{"key":"3541_CR56","doi-asserted-by":"publisher","DOI":"10.1177\/10760296251335967","volume":"31","author":"Z Xue","year":"2025","unstructured":"Xue Z, Liao S, Fan H, Shen Y, Nie Z. A systematic review of factor\u00a0XI\/XIa inhibitors versus direct oral anticoagulants in patients with atrial fibrillation. Clin Appl Thromb Hemost. 2025;31:10760296251335967. https:\/\/doi.org\/10.1177\/10760296251335967.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"10357","key":"3541_CR57","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, et al. Factor\u00a0XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase\u00a02b trial. Lancet. 2022;400(10357):997\u20131007. https:\/\/doi.org\/10.1016\/S0140-6736(22)01588-4.","journal-title":"Lancet"},{"issue":"16","key":"3541_CR58","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","volume":"146","author":"SV Rao","year":"2022","unstructured":"Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase\u00a02, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor\u00a0XIa inhibitor Asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022;146(16):1196\u2013206. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061612.","journal-title":"Circulation"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03541-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:37:24Z","timestamp":1778229444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03541-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3541"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03541-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rosemary B. Falama, Lisa R. Matsumoto, Marie E. Piatski, Lukas Seifer, Aditya Malhotra, Owen J.T. McCarty, and Joseph J. Shatzel declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval was not required for this study because it is a review of previously published literature. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}